Quantcast

Latest Bupropion/zonisamide Stories

2014-07-31 08:35:39

SAN DIEGO, July 31, 2014 /PRNewswire/ -- Orexigen® Therapeutics, Inc. (Nasdaq: OREX) will announce financial results for the second quarter 2014, on Thursday, August 7, 2014 before markets open. The announcement will be followed by a live webcast and conference call at 8:00 a.m. Eastern time (5:00 a.m. Pacific time). Orexigen management will host the call and webcast to discuss financial results and recent business highlights. The live call may be accessed by calling (800) 708-4540...

2014-07-30 08:32:50

SAN DIEGO, July 30, 2014 /PRNewswire/ -- Orexigen Therapeutics, Inc. (Nasdaq: OREX) today announced it has received the Day 180 List of Outstanding Issues (LOI) from the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) for the NB32 Marketing Authorization Application (MAA). NB32 (naltrexone sustained release (SR) / bupropion SR) is an investigational drug candidate being evaluated for weight loss. The key questions of the earlier Day 120 time point...

2014-06-13 08:24:12

SAN DIEGO, June 13, 2014 /PRNewswire/ -- Orexigen® Therapeutics, Inc. (Nasdaq: OREX) today announced that management will present a company overview at the Wells Fargo Securities 2014 Healthcare Conference in Boston. The presentation is scheduled for Wednesday, June 18(th) at 1:50 p.m. EDT. To listen to the live webcast or a replay of the presentation, please visit the Investor Relations section of the Company's Web site at www.orexigen.com. A replay will be available for 14 days...

2014-06-11 08:28:16

- Agreement needs to be reached on the post-marketing obligation for continued evaluation of CV outcomes - SAN DIEGO, June 11, 2014 /PRNewswire/ -- Orexigen® Therapeutics, Inc. (Nasdaq: OREX) today announced that the United States Food and Drug Administration (FDA) has extended its review of the resubmitted New Drug Application (NDA) for NB32, the Company's investigational medication being evaluated for weight loss. The new Prescription Drug User Fee Act (PDUFA) action date has...

2014-06-02 08:29:51

- FDA will Adjust the PDUFA Date by One Day Based on Revised Calendar Calculation - SAN DIEGO, June 2, 2014 /PRNewswire/ -- Orexigen® Therapeutics, Inc. (Nasdaq: OREX), today announced that the United States Food and Drug Administration (FDA) has informed the Company that the FDA intends to reassign the Prescription Drug User Fee Act (PDUFA) action date for the NB32 New Drug Application to June 11, 2014, one day beyond the original assignment. The FDA noted that due to an...

2014-05-09 16:24:48

SAN DIEGO, May 9, 2014 /PRNewswire/ -- Orexigen® Therapeutics, Inc. (Nasdaq: OREX) today announced that management will present a company overview at the Bank of America Merrill Lynch 2014 Health Care Conference in Las Vegas. The presentation is scheduled for Wednesday, May 14(th) at 3 p.m. Pacific Time. To listen to the live webcast or a replay of the presentation, please visit the Investor Relations section of the Company's Web site at www.orexigen.com. A replay will be available...

2014-05-08 16:26:47

SAN DIEGO, May 8, 2014 /PRNewswire/ -- Orexigen(®) Therapeutics, Inc. (Nasdaq: OREX), a biopharmaceutical company focused on the treatment of obesity, today announced corporate and financial results for the first quarter ended March 31, 2014. "With the June 10 PDUFA date for NB32 quickly approaching, we are excited to be working closely with our partner for North America, Takeda Pharmaceuticals, on final preparations to launch NB32, if approved, with a field force of approximately 900 sales...

2014-05-01 08:36:45

SAN DIEGO, May 1, 2014 /PRNewswire/ -- Orexigen® Therapeutics, Inc. (Nasdaq: OREX), a biopharmaceutical company focused on the treatment of obesity, will announce financial results for the first quarter 2014, on Thursday, May 8, 2014 after the markets close. The announcement will be followed by a live webcast and conference call at 5:00 p.m. Eastern time (2:00 p.m. Pacific time). Orexigen management will host the call and webcast to discuss financial results and recent business...

2014-03-12 16:26:21

SAN DIEGO, March 12, 2014 /PRNewswire/ -- Orexigen(®) Therapeutics, Inc. (Nasdaq: OREX), a biopharmaceutical company focused on the treatment of obesity, today announced corporate and financial results for the fourth quarter and year ended December 31, 2013. "The successful interim results of the Light Study give us confidence in the prospects for NB32 approvals in the U.S., Europe, and ultimately around the globe, and we believe the study creates value in addition to providing support for...

2014-03-03 08:32:10

SAN DIEGO, March 3, 2014 /PRNewswire/ -- Orexigen® Therapeutics, Inc. (Nasdaq: OREX), a biopharmaceutical company focused on the treatment of obesity, will announce financial results for the full year and fourth quarter 2013, on Wednesday, March 12, 2014 after the markets close. The announcement will be followed by a live webcast and conference call at 5:00 p.m. Eastern time (2:00 p.m. Pacific time). Orexigen management will host the call and webcast to discuss financial results...


Word of the Day
Cthulhu
  • A gigantic fictional humanoid alien god being described with a head resembling an octopus and dragon wings and claws, around whom an insane cult developed.
  • Pertaining to the mythos of Cthulhu and additional otherworldly beings created by H. P. Lovecraft or inspired by his writings and imitators.
This word was invented in 1926 by H.P. Lovecraft for his short story, 'The Call of Cthulhu.' 'Cthulhu' may be based on the word 'chthonic,' which in Greek mythology refers to the underworld.
Related